CollPlant to Acquire Nano-X Imaging for $126M
Ticker: CLGN · Form: 6-K · Filed: Jun 6, 2024 · CIK: 1631487
Sentiment: mixed
Topics: acquisition, merger, healthcare, biotechnology
TL;DR
CollPlant buying Nano-X for $126M in stock to merge imaging & regen med.
AI Summary
CollPlant Biotechnologies Ltd. announced on June 6, 2024, that it has entered into a binding agreement to acquire Nano-X Imaging Ltd. for approximately $126 million in an all-stock transaction. This strategic move aims to create a comprehensive medical imaging and regenerative medicine company. The transaction is expected to close in the second half of 2024, subject to customary closing conditions.
Why It Matters
This acquisition combines a medical imaging technology company with a regenerative medicine company, potentially creating a synergistic entity with a broader market reach and diversified revenue streams in the healthcare sector.
Risk Assessment
Risk Level: medium — The acquisition is an all-stock deal and subject to closing conditions, introducing integration risks and potential market reception challenges.
Key Numbers
- $126M — Acquisition Value (CollPlant's proposed purchase price for Nano-X Imaging.)
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Acquiring company
- Nano-X Imaging Ltd. (company) — Target company
- $126 million (dollar_amount) — Acquisition value
- June 6, 2024 (date) — Announcement date
- second half of 2024 (date) — Expected closing period
FAQ
What is the total value of the proposed acquisition of Nano-X Imaging by CollPlant?
The total value of the proposed acquisition is approximately $126 million.
What type of transaction is this acquisition?
This is an all-stock transaction.
When is the acquisition expected to close?
The transaction is expected to close in the second half of 2024.
What is the strategic rationale behind this acquisition?
The acquisition aims to create a comprehensive medical imaging and regenerative medicine company.
What are the primary business areas of the combined entity?
The combined entity will focus on medical imaging and regenerative medicine.
Filing Stats: 283 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-06-06 07:04:11
Filing Documents
- ea0207443-6k_collpla.htm (6-K) — 10KB
- ea020744301ex99-1_collpla.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-050193.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: June 6, 2024 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2